|
1
|
Hedayatizadeh-Omran A, Rafiei A, Khajavi
R, Alizadeh-Navaei R, Mokhberi V and Moradzadeh K: Association
between ghrelin gene (Leu72Met) polymorphism and ghrelin serum
level with coronary artery diseases. DNA Cell Biol. 33:95–101.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Safdari R, Maleki M and Ghorbani V:
Comparison of Cardiovascular Diseases Classification in some
developed countries with Iran. Payavard Salamat. 3:50–56. 2009.
|
|
3
|
Kounis NG, Soufras GD, Tsigkas G and
Hahalis G: White blood cell counts, leukocyte ratios, and
eosinophils as inflammatory markers in patients with coronary
artery disease. Clin Appl Thromb Hemost. 21:139–143. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nasehi MM, Moosazadeh M, Âmiresmaeili M,
Parsaee M, Zakizadeh R and Mirzajani M: Prevalence of five main
risk factors of non-communicable diseases in mazandaran province: A
population based study. J Mazandaran Univ Med Sci. 21:193–202.
2012.
|
|
5
|
Boutayeb A: The double burden of
communicable and non-communicable diseases in developing countries.
Trans R Soc Trop Med Hyg. 100:191–199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kolahdoozan S, Sadjadi A, Radmard AR and
Khademi H: Five common cancers in Iran. Arch Iran Med. 13:143–146.
2010.PubMed/NCBI
|
|
7
|
Naghavi M, Abolhassani F, Pourmalek F,
Jafari N, Lakeh Moradi M, Eshrati B, Hezaveh Mahdavi N, Kazemeini
H, Banihashemi Tehrani A and Shoaee SH: The burden of disease and
injury in Iran in the year 2003. Iranian J Epidemiol. 4:1–19.
2008.
|
|
8
|
World Health Organization: Noncommunicable
diseases (NCD) country profiles. 2014.http://www.who.int/nmh/countries/irn_en.pdf?ua=1
|
|
9
|
Hedayatizadeh-Omran A, Rafiei A,
Alizadeh-Navaei R, Tehrani M, Valadan R, Moradzadeh K, Panbechi M
and Taghavi SM: Role of HER2 in brain metastasis of breast cancer:
A systematic review and meta-analysis. Asian Pac J Cancer Prev.
16:1431–1434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rasouli M, Kiasari Mohseni A, Mokhberi V,
Bagheri B, Daneshpour NS, Shariati R, et al: Global risk assessment
of coronary heart disease using Framingham's scores for major risk
factors. Majallah-i Danishgah-i Ulum-i Pizishki-i Mazandaran.
15:49–62. 2006.
|
|
11
|
Hatmi ZN, Tahvildari S, Motlag Gafarzadeh
A and Kashani Sabouri A: Prevalence of coronary artery disease risk
factors in Iran: A population based survey. BMC Cardiovasc Disord.
7:322007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golchin Mafi M, Ghaderian SMH,
Akhavan-Niaki H, Jalalian R, Heidari L and Salami SA: Analysis of
two CDKN2B-AS polymorphisms in relation to coronary artery disease
patients in north of Iran. Int J Mol Cell Med. 6:31–37.
2017.PubMed/NCBI
|
|
13
|
den Hoed M, Strawbridge RJ, Almgren P,
Gustafsson S, Axelsson T, Engström G, de Faire U, Hedblad B,
Humphries SE, Lindgren CM, et al: GWAS-identified loci for coronary
heart disease are associated with intima-media thickness and plaque
presence at the carotid artery bulb. Atherosclerosis. 239:304–310.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bergamaschi D, Gasco M, Hiller L, Sullivan
A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et
al: p53 polymorphism influences response in cancer chemotherapy via
modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kung CP, Leu JI, Basu S, Khaku S,
Anokye-Danso F, Liu Q, George DL, Ahima RS and Murphy ME: The P72R
polymorphism of p53 predisposes to obesity and metabolic
dysfunction. Cell Reports. 14:2413–2425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawashima H, Takatori H, Suzuki K, Iwata
A, Yokota M, Suto A, Minamino T, Hirose K and Nakajima H: Tumor
suppressor p53 inhibits systemic autoimmune diseases by inducing
regulatory T cells. J Immunol. 191:3614–3623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung WC, Lee KM, Lee BI, Chun JS, Lee SY,
Chang UI, Park SH, Yang JM, Choi KY and Chung IS: P53 genetic
polymorphism of gastric cancer in Korea. Korean J Intern Med
(Korean Assoc Intern Med). 21:28–32. 2006.
|
|
18
|
Kumar V, Abbas AK and Aster JC: Robbins
and Cotran Pathologic Basis of Disease. 9th edition. Elsevier; New
York, NY: 2015
|
|
19
|
Naccarati A, Polakova V, Pardini B,
Vodickova L, Hemminki K, Kumar R and Vodicka P: Mutations and
polymorphisms in TP53 gene - an overview on the role in colorectal
cancer. Mutagenesis. 27:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGraw KL, Cluzeau T, Sallman DA, Basiorka
AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M,
Sokol L, et al: TP53 and MDM2 single nucleotide polymorphisms
influence survival in non-del(5q) myelodysplastic syndromes.
Oncotarget. 6:34437–34445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Doosti A, Dehkordi Ghasemi P, Zamani M,
Taheri S, Banitalebi M and Mahmoudzadeh M: Association of the p53
codon 72 polymorphism with colorectal cancer in South West of Iran.
Sci Res Essays. 6(10): 58972011.
|
|
22
|
Kung CP and Murphy ME: The role of the p53
tumor suppressor in metabolism and diabetes. J Endocrinol.
231:R61–R75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu DP, Song H and Xu Y: A common gain of
function of p53 cancer mutants in inducing genetic instability.
Oncogene. 29:949–956. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sadeghi Najjar R, Azimzadeh P, Vahedi M,
Mirsattari D, Molaei M, Mohebbi S, et al: Profile and frequency of
p53 gene alterations in gastritis lesions from Iran 2010. 65–75
|
|
25
|
Soleimani A, Rahmani Y, Farshchian N,
Delpisheh A, Khassi K, Shahmohammadi A and Amirifard N: The
Evaluation of p53 polymorphism at codon 72 and association with
breast cancer in Iran: A systematic review and meta-analysis. J
Cancer Prev. 21:288–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang W, Zhou X, Nie S, Yang Z, Zhu H, Wu
X, Zhao R and Luo Y: Association of p53 Arg72Pro polymorphism with
gastric cancer: A meta-analysis. Biomarkers. 17:597–603. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kankova K: Association of the Arg72Pro
polymorphism in p53 with progression of diabetic nephropathy in
T2DM subjects. J Nephrol Ther. 4:1532014. View Article : Google Scholar
|
|
28
|
Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan
Z, Lin B, Lu Y and Xie Y: p53 codon 72 polymorphism predicts the
pathologic response to neoadjuvant chemotherapy in patients with
breast cancer. Clin Cancer Res. 11:7328–7333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vikhanskaya F, Siddique MM, Lee Kei M,
Broggini M and Sabapathy K: Evaluation of the combined effect of
p53 codon 72 polymorphism and hotspot mutations in response to
anticancer drugs. Clin Cancer Res. 11:4348–4356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Frank AK, Leu JI, Zhou Y, Devarajan K,
Nedelko T, Klein-Szanto A, Hollstein M and Murphy ME: The codon 72
polymorphism of p53 regulates interaction with NF-{kappa}B and
transactivation of genes involved in immunity and inflammation. Mol
Cell Biol. 31:1201–1213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alkhalaf M, Al-Bustan S, Hamoda H and
Abdella N: Polymorphism of p53 gene codon 72 in Kuwaiti with
coronary artery disease and diabetes. Int J Cardiol. 115:1–6. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gloria-Bottini F, Banci M, Saccucci P,
Neri A, Bottini E and Magrini A: p53 codon 72 polymorphism and
coronary artery disease: Evidence of interaction with
ACP1. Med Sci Monit. 18:CR712–CR715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Manfredi S, Masetti S, Botto N, Colombo
MG, Terrazzi M, Vassalle C, Biagini A and Andreassi MG: P53 codon
72 polymorphism in coronary artery disease: No evidence for
association with increased risk or micronucleus frequency. Environ
Mol Mutagen. 40:110–115. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Judkins MP: Selective coronary
arteriography. I. A percutaneous transfemoral technic. Radiology.
89:815–824. 1967. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Khan S, Phulukdaree A, Ramkaran P, Moodley
D and Chuturgoon AA: The Arg72 variant of the p53 functional
polymorphism (rs1042522) is associated with coronary artery disease
in young South Africans of Indian ancestry. Gene. 593:261–264.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ara S, Lee PS, Hansen MF and Saya H: Codon
72 polymorphism of the TP53 gene. Nucleic Acids Res. 18:49611990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morris JA and Gardner MJ: Calculating
confidence intervals for relative risks (odds ratios) and
standardised ratios and rates. Br Med J (Clin Res Ed).
296:1313–1316. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sikka S and Sikka P: Association of human
papilloma virus 16 infection and p53 polymorphism among tobacco
using oral leukoplakia patients: A clinicopathologic and genotypic
study. Int J Prev Med. 5:430–438. 2014.PubMed/NCBI
|
|
39
|
Sadeghi M, Haghdoost AA, Bahrampour A and
Dehghani M: Modeling the burden of cardiovascular diseases in Iran
from 2005 to 2025: The impact of demographic changes. Iran J Public
Health. 46:506–516. 2017.PubMed/NCBI
|
|
40
|
Maracy MR, Isfahani MT, Kelishadi R,
Ghasemian A, Sharifi F, Shabani R, Djalalinia S, Majidi S, Ansari
H, Asayesh H, et al: Burden of ischemic heart diseases in Iran,
1990–2010: Findings from the global burden of disease study 2010. J
Res Med Sci. 20:1077–1083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ebrahimi M, Kazemi-Bajestani SM,
Ghayour-Mobarhan M and Ferns GA: Coronary artery disease and its
risk factors status in Iran: A review. Iran Red Crescent Med J.
13:610–623. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hirashiki A, Yamada Y, Murase Y, Suzuki Y,
Kataoka H, Morimoto Y, Tajika T, Murohara T and Yokota M:
Association of gene polymorphisms with coronary artery disease in
low- or high-risk subjects defined by conventional risk factors. J
Am Coll Cardiol. 42:1429–1437. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Satti HS, Hussain S and Javed Q:
Association of interleukin-6 gene promoter polymorphism with
coronary artery disease in Pakistani families.
ScientificWorldJournal. 2013:5383652013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saccucci P, Banci M, Amante A, Bottini E
and Gloria-Bottini F: Coronary artery disease: Evidence of
interaction between PTPN22 and p53 genetic polymorphisms.
Cardiology. 120:166–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gu J, Spitz MR, Zhao H, Lin J, Grossman
HB, Dinney CP and Wu X: Roles of tumor suppressor and telomere
maintenance genes in cancer and aging - an epidemiological study.
Carcinogenesis. 26:1741–1747. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Grizzi F and Chiriva-Internati M: Cancer:
Looking for simplicity and finding complexity. Cancer Cell Int.
6:42006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dastjerdi MN, Hasanzadeh M, Talebi A and
Akbari M: Investigation of p53 codon 72 polymorphism in patients
with nonmelanoma skin cancers in Isfahan. Majallah-i Danishkadah-i
Pizishki-i Isfahan. 29:679–685. 2011.
|
|
48
|
Malekzadeh R, Bishehsari F, Mahdavinia M
and Ansari R: Epidemiology and molecular genetics of colorectal
cancer in Iran: A review. Arch Iran Med. 12:161–169.
2009.PubMed/NCBI
|
|
49
|
Bonafé M, Ceccarelli C, Farabegoli F,
Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G,
Olivieri F, et al: Retention of the p53 codon 72 arginine allele is
associated with a reduction of disease-free and overall survival in
arginine/proline heterozygous breast cancer patients. Clin Cancer
Res. 9:4860–4864. 2003.PubMed/NCBI
|
|
50
|
Neamatzadeh H, Soleimanizad R, Atefi A,
Zare-Shehneh M, Gharibi S, Shekari A and Rahimzadeh AB: Association
between p53 codon 72 (Arg72Pro) polymorphism and primary open-angle
glaucoma in Iranian patients. Iran Biomed J. 19:51–56.
2015.PubMed/NCBI
|
|
51
|
Moradi MT, Salehi Z, Aminian K and
Yazdanbod A: Effects of p53 codon 72 and MDM2 SNP309 polymorphisms
on gastric cancer risk among the Iranian population. Asian Pac J
Cancer Prev. 15:7413–7417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hedayatizadeh-Omran A, Alizadeh-Navaei R,
Janbabaei G, Omrani-Nava V, Hasheminasab Y, Amjadi O and Tehrani M:
Association of P53 gene polymorphism with gastric cancer in
Northern Iran as a high-risk region. Biomed Rep. 8:433–438.
2018.PubMed/NCBI
|
|
53
|
Mojtahedi Z, Hashemi SB, Khademi B, Karimi
M, Haghshenas MR, Fattahi MJ and Ghaderi A: p53 codon 72
polymorphism association with head and neck squamous cell
carcinoma. Rev Bras Otorrinolaringol (Engl Ed). 76:316–320.
2010.
|
|
54
|
Sina M, Pedram M, Ghojazadeh M, Kochaki A
and Aghbali A: P53 gene codon 72 polymorphism in patients with oral
squamous cell carcinoma in the population of northern Iran. Med
Oral Patol Oral Cir Bucal. 19:e550–e555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gerayli S, Pasdar A, Rostami S, Sepahi S,
Hoseini Mousalreza S, Jahanian R, Gholoobi A, Meshkat Z and Ahadi
M: Association of codon 72 of p53 gene polymorphism with chronic
hepatitis C virus infection: A case control study. J Cell Mol Res.
8:46–51. 2016.
|
|
56
|
Huxley RR, Ansary-Moghaddam A, Clifton P,
Czernichow S, Parr CL and Woodward M: The impact of dietary and
lifestyle risk factors on risk of colorectal cancer: A quantitative
overview of the epidemiological evidence. Int J Cancer.
125:171–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ahmad A, Banerjee S, Wang Z, Kong D,
Majumdar AP and Sarkar FH: Aging and inflammation: Etiological
culprits of cancer. Curr Aging Sci. 2:174–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lopez-Candales A, Burgos Hernández PM,
Hernandez-Suarez DF and Harris D: Linking chronic inflammation with
cardiovascular disease: From normal aging to the metabolic
syndrome. J Nat Sci. 3:e3412017.PubMed/NCBI
|
|
59
|
Gloria-Bottini F, Banci M, Saccucci P,
Nardi P, Scognamiglio M, Papetti F, Magrini A, Pellegrino A,
Bottini E and Chiariello L: p53 codon 72 polymorphism and coronary
artery disease: Evidence of association with left ventricular
ejection fraction. Am J Med Sci. 343:127–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Khodadadi A, Shafeie Mir A, Eslami MB,
Razavi A and Hekmat K: An investigation upon the effectiveness of
LVA-7220 as an immunomodulator on chronic ulcerative colities in
rats. Koomesh. 4:151–157. 2003.
|
|
61
|
Vietri MT, Riegler G, Ursillo A, Caserta
L, Cioffi M and Molinari AM: p53 codon 72 polymorphism in patients
affected with ulcerative colitis. J Gastroenterol. 42:456–460.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Vaji S, Salehi Z and Aminian K:
Association of p53 codon 72 genetic polymorphism with the risk of
ulcerative colitis in northern Iran. Int J Colorectal Dis.
26:235–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lagares MH, Silva KSF, Barbosa AM,
Rodrigues DA, Costa IR, Martins JVM, Morais MP, Campedelli FL and
Moura KKVO: Analysis of p53 gene polymorphism (codon 72) in
symptomatic patients with atherosclerosis. Genet Mol Res. 16:1–9.
2017. View Article : Google Scholar
|
|
64
|
Caamaño J, Saavedra N, Jaramillo PC, Lanas
C, Lanas F and Salazar LA: TP53 codon 72 polymorphism is associated
with coronary artery disease in Chilean subjects. Med Princ Pract.
20:171–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ye H, Li X, Wang L, Liao Q, Xu L, Huang Y,
Xu L, Xu X, Chen C, Wu H, et al: Genetic associations with coronary
heart disease: Meta-analyses of 12 candidate genetic variants.
Gene. 531:71–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Frostegård J: Atherosclerosis in patients
with autoimmune disorders. Arterioscler Thromb Vasc Biol.
25:1776–1785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Renjith AS, Marwaha V, Aggarwal N, Koshy
V, Singal VK and Kumar KVSH: Prevalence of left ventricular
dysfunction in rheumatoid arthritis. J Family Med Prim Care.
6:622–626. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ostanek L, Ostanek-Pańka M,
Bobrowska-Snarska D, Bińczak-Kuleta A, Fischer K, Kaczmarczyk M,
Ciechanowicz A and Brzosko M: PTPN22 1858C>T gene polymorphism
in patients with SLE: Association with serological and clinical
results. Mol Biol Rep. 41:6195–6200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Abbasi Z, Nezhad Kazemi SR,
Pourmahdi-Broojeni M and Rajaei E: Association of PTPN22 rs2476601
Polymorphism with rheumatoid arthritis and celiac disease in
Khuzestan province, southwestern Iran. Iran Biomed J. 21:61–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jafari-Adli S, Jouyandeh Z, Qorbani M,
Soroush A, Larijani B and Hasani-Ranjbar S: Prevalence of obesity
and overweight in adults and children in Iran; a systematic review.
J Diabetes Metab Disord. 13:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Davoodi SH, Malek-Shahabi T,
Malekshahi-Moghadam A, Shahbazi R and Esmaeili S: Obesity as an
important risk factor for certain types of cancer. Iran J Cancer
Prev. 6:186–194. 2013.PubMed/NCBI
|
|
72
|
Ahmadi A, Mobasheri M and Soori H:
Prevalence of major coronary heart disease risk factors in Iran.
Int J Epidemiol Res. 1:3–8. 2014.
|
|
73
|
Monfared AB, Hatami H and Isabeiglou H:
Prevalence and associated factors of overweight and obesity in
reproductive-aged women in Rasht. J Health Field. 4:39–46.
2016.
|
|
74
|
Shahri Mahdavi SM, Khalili Z, Sadrollahi A
and Saadati B: Prevalence of risk factors for cardiovascular
disease among elderly people in Kashan city, Iran, 2014. Cardiovasc
Nurs J. 3:6–13. 2014.
|
|
75
|
Sadeghi M, Talaei M, Oveisgharan S, Rabiei
K, Dianatkhah M, Bahonar A and Sarrafzadegan N: The cumulative
incidence of conventional risk factors of cardiovascular disease
and their population attributable risk in an Iranian population:
The Isfahan Cohort Study. Adv Biomed Res. 3:2422014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Italian National Institute of Statistics:
Diabetes in Italy (2000–2016). https://www.istat.it/it/files//2017/07/Report_Diabetes_En_def.pdf
|
|
77
|
Eschwege E, Basdevant A, Crine A, Moisan C
and Charles MA: Type 2 diabetes mellitus in France in 2012: Results
from the ObEpi survey. Diabetes Metab. 41:55–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Obesity and the Economics of Prevention:
Fit not Fat - France Key Facts. http://www.oecd.org/els/health-systems/obesityandtheeconomicsofpreventionfitnotfat-francekeyfacts.htm
|
|
79
|
Rahmani A, Sayehmiri K, Asadollahi K,
Sarokhani D, Islami F and Sarokhani M: Investigation of the
prevalence of obesity in Iran: A systematic review and
meta-analysis study. Acta Med Iran. 53:596–607. 2015.PubMed/NCBI
|
|
80
|
Esteghamati A, Larijani B, Aghajani MH,
Ghaemi F, Kermanchi J, Shahrami A, Saadat M, Esfahani EN, Ganji M,
Noshad S, et al: Diabetes in Iran: Prospective analysis from first
nationwide diabetes report of National Program for Prevention and
Control of Diabetes (NPPCD-2016). Sci Rep. 7:134612017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gikas A, Lambadiari V, Sotiropoulos A,
Panagiotakos D and Pappas S: Prevalence of major cardiovascular
risk factors and coronary heart disease in a sample of Greek
adults: The saronikos study. Open Cardiovasc Med J. 10:69–80. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Dhingra R and Vasan RS: Age as a risk
factor. Med Clin North Am. 96:87–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jackson CF and Wenger NK: Cardiovascular
disease in the elderly. Rev Esp Cardiol. 64:697–712. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yang HH, Chen Y and Gao CY: Associations
of P2Y12R gene polymorphisms with susceptibility to coronary heart
disease and clinical efficacy of antiplatelet treatment with
clopidogrel. Cardiovasc Ther. 34:460–467. 2016. View Article : Google Scholar : PubMed/NCBI
|
